Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Finished Goods (2016 - 2025)

Phibro Animal Health (PAHC) has 13 years of Finished Goods data on record, last reported at $309.7 million in Q4 2025.

  • For Q4 2025, Finished Goods rose 21.43% year-over-year to $309.7 million; the TTM value through Dec 2025 reached $309.7 million, up 21.43%, while the annual FY2025 figure was $253.8 million, 49.69% up from the prior year.
  • Finished Goods reached $309.7 million in Q4 2025 per PAHC's latest filing, up from $279.6 million in the prior quarter.
  • Across five years, Finished Goods topped out at $309.7 million in Q4 2025 and bottomed at $133.2 million in Q1 2021.
  • Average Finished Goods over 5 years is $190.6 million, with a median of $170.8 million recorded in 2023.
  • Peak YoY movement for Finished Goods: fell 3.0% in 2024, then soared 63.76% in 2025.
  • A 5-year view of Finished Goods shows it stood at $147.6 million in 2021, then increased by 16.81% to $172.4 million in 2022, then rose by 7.05% to $184.6 million in 2023, then surged by 38.16% to $255.0 million in 2024, then grew by 21.43% to $309.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $309.7 million in Q4 2025, $279.6 million in Q3 2025, and $253.8 million in Q2 2025.